Latest Biotechnology News

Page 6 of 115
Entropy Neurodynamics says all six patients in its early Phase 2 binge eating disorder cohort retained clinically meaningful improvement 12 weeks after treatment. The company is now widening TRP-8803’s development program while operating with $3.626 million in cash and an undrawn $2.6 million facility.
Ada Torres
Ada Torres
28 Oct 2026
ASF Group finished FY2026 with A$5.19 million in cash, no outstanding borrowings and a materially stronger net asset position after selling several investments. But the A$4.09 million profit was still largely disposal-led, while operating cash flow remained negative and recurring revenue declined.
Victor Sage
Victor Sage
27 Oct 2026
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026
Cynata Therapeutics ended September with just A$175,000 in cash after a A$1.316 million quarterly operating drain, but says sweeping cuts and fresh funding could extend its runway into FY2028. The biotech has now reduced its workforce to zero, repaid its R&D loan and shifted focus to finding value for its Cymerus platform.
Ada Torres
Ada Torres
27 Oct 2026
Skin Elements has secured firm commitments for a A$700,000 placement to fund working capital and commercialisation across its natural biotechnology portfolio. The raising includes 318.2 million free-attaching options, making shareholder approval and future dilution important next steps.
Ada Torres
Ada Torres
27 Oct 2026
Clarity Pharmaceuticals has completed planned recruitment for its 383-participant CLARIFY Phase III trial of 64Cu-SAR-bisPSMA, moving the diagnostic candidate into patient follow-up. Topline sensitivity and specificity data are expected in the first half of 2027 and could support a US FDA application.
Ada Torres
Ada Torres
27 Oct 2026
NeuroScientific Biopharmaceuticals has secured favourable US FDA feedback on its planned StemSmart Phase 2 trial for refractory Crohn’s disease, while appointing a clinical research partner and advancing manufacturing validation. The company enters the next phase with $3.91 million in cash and a targeted trial start by the end of 2026.
Ada Torres
Ada Torres
27 Oct 2026
Arovella has moved its off-the-shelf CAR-iNKT therapy ALA-101 into human testing, dosing the first patient in the phase 1 SAPPHIRE trial. The study will now test safety and early signs of activity, with initial data expected in early 2027.
Ada Torres
Ada Torres
27 Oct 2026
Argent BioPharma has granted Thai Phytomed International exclusive global commercialisation rights to four cannabis genotypes under a 10-year agreement. The deal preserves Argent’s ownership, but royalties depend on TPI generating profitable sales and securing approvals across multiple markets.
Victor Sage
Victor Sage
27 Oct 2026
Avenira’s approximately $48.9 million rights issue has received more than $44 million in applications and funds ahead of its 30 October close. The raise, combined with $85 million in debt facilities, is intended to fund the Wonarah Project’s direct shipping ore phase.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Radiopharm Theranostics has received an $8 million advance against its anticipated FY26 Australian R&D tax incentive, giving the clinical-stage company additional funding for trials and working capital. The facility carries commercial interest and must be repaid by 26 October 2027.
Victor Sage
Victor Sage
26 Oct 2026
Actinogen Medical has received an A$10.84 million R&D tax rebate, leaving it with A$21.9 million in pro forma cash and no debt just weeks before its pivotal Alzheimer’s readout. The company says topline XanaMIA results remain due in mid-November.
Ada Torres
Ada Torres
26 Oct 2026

Browse the archive

Full archive